Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010.

[1]  S. A. Nishioka,et al.  [Drug interchangeability: clinical approach and consumer's point of view]. , 2006, Revista de saude publica.

[2]  D Ross-Degnan,et al.  Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis , 2009, The Lancet.

[3]  L. Gilson,et al.  The terrain of health policy analysis in low and middle income countries: a review of published literature 1994–2007 , 2008, Health policy and planning.

[4]  A. Awaisu,et al.  Evaluating Community Pharmacists' Perceptions and Practices on Generic Medicines: A Pilot Study from Peninsular Malaysia , 2008 .

[5]  M. Gossell-Williams.  Generic substitutions: a 2005 survey of the acceptance and perceptions of physicians in Jamaica. , 2007, The West Indian medical journal.

[6]  R. Zeckhauser,et al.  Generic script share and the price of brand-name drugs: the role of consumer choice , 2009, International Journal of Health Care Finance and Economics.

[7]  Federico Tobar.  Economía de los medicamentos genéricos en América Latina , 2008 .

[8]  L. Kumaranayake,et al.  Do they work? Regulating for-profit providers in Zimbabwe. , 2000, Health policy and planning.

[9]  E. Hansen,et al.  Prescription habits of dispensing and non-dispensing doctors in Zimbabwe. , 2002, Health policy and planning.

[10]  Gabriela Bevilacqua,et al.  Procurement of generic medicines in a medium size municipality. , 2011, Revista de saude publica.

[11]  Panos Kanavos,et al.  Encouraging the use of generic medicines: implications for transition economies. , 2002, Croatian medical journal.

[12]  F. Tobar.  [Economy of generic drugs in Latin America]. , 2008, Revista panamericana de salud publica = Pan American journal of public health.

[13]  G. F. Hogan.  Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984. , 1985, American journal of hospital pharmacy.

[14]  K. Timmermans.  Harmonization, Regulation, and Trade: Interactions in the Pharmaceutical Field , 2004, International journal of health services : planning, administration, evaluation.

[15]  D. Ross-Degnan,et al.  Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence. , 2011, Health policy.

[16]  K. Wasan,et al.  Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals. , 2011, Journal of pharmaceutical sciences.

[17]  L. M. Pels,et al.  Experience of a medicines reference-pricing model. , 2004, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[18]  M. Hassali,et al.  Evaluating community pharmacists' perceptions of future generic substitution policy implementation: a national survey from Malaysia. , 2010, Health policy.

[19]  A D Oxman,et al.  Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. , 2006, The Cochrane database of systematic reviews.

[20]  Dan Ariely,et al.  Commercial features of placebo and therapeutic efficacy. , 2008, JAMA.

[21]  L. Gauvin,et al.  Public and private sector responses to essential drugs policies: a multilevel analysis of drug prescription and selling practices in Mali. , 2003, Social science & medicine.

[22]  N. Ford,et al.  Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand , 2007, AIDS.

[23]  R. Laing,et al.  Cost savings of switching private sector consumption from originator brand medicines to generic equivalents , 2010 .

[24]  B. McPake,et al.  Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings. , 2010, Health policy and planning.

[25]  J. Rovira,et al.  Generics in Latin America: Trends and Regulation , 2008 .

[26]  T. Ensor,et al.  Overcoming barriers to health service access: influencing the demand side. , 2004, Health policy and planning.

[27]  S. Tantivess,et al.  Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: analysis of the effect of TRIPs-Plus proposal. , 2009, Health policy.

[28]  Hugo Carradinha.  Tendering Short-Term Pricing Policies and the Impact on Patients, Governments and the Sustainability of the Generic Medicines Industry , 2009 .

[29]  Friedhelm Nachreiner,et al.  Health and psychosocial effects of flexible working hours. , 2004, Revista de saude publica.

[30]  Mareni Rocha Farias,et al.  Aquisição de medicamentos genéricos em município de médio porte , 2011 .

[31]  W. Kaplan,et al.  Paying for pharmaceutical registration in developing countries. , 2003, Health policy and planning.

[32]  S. Brophy,et al.  Interventions for latent autoimmune diabetes (LADA) in adults. , 2011, The Cochrane database of systematic reviews.

[33]  A. Lafond,et al.  A guide to monitoring and evaluation of capacity-building interventions in the health sector in developing countries. , 2003 .

[34]  P. Kraipornsak,et al.  Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand. , 2001, Bulletin of the World Health Organization.

[35]  S. Ratanawijitrasin,et al.  Effective Drug Regulation: A Multicountry Study , 2002 .

[36]  F. Haaijer-Ruskamp,et al.  Intervention research in rational use of drugs: a review. , 1999, Health policy and planning.

[37]  Cf Lee,et al.  PMH80 THE CHANGE OF PRICES AND EXPENDITURES OFTHE ORIGINAL AND GENERIC DRUGS OF FLUOXETINE—A LONGITUDINAL ANALYSIS ON REIMBURSEMENT DATABASE OFTHE NATIONAL HEALTH INSURANCE , 2008 .

[38]  Davi Rumel,et al.  Intercambialidade de medicamentos: abordagem clínica e o ponto de vista do consumidor , 2006 .

[39]  J. Morin.  Tripping up TRIPS Debates IP and Health in Bilateral Agreements , 2006 .

[40]  M. A. Oliveira,et al.  A proposal for measuring the degree of public health-sensitivity of patent legislation in the context of the WTO TRIPS Agreement. , 2007, Bulletin of the World Health Organization.

[41]  M. Dybul,et al.  Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. , 2010, JAMA.

[42]  R. Summers,et al.  Randomized, controlled trial of prescribing training in a South African province , 2001, Medical education.

[43]  S. Soumerai,et al.  Do national medicinal drug policies and essential drug programs improve drug use?: a review of experiences in developing countries. , 2001, Social science & medicine.

[44]  A. Oxman,et al.  Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. , 2014, The Cochrane database of systematic reviews.

[45]  H. Lofgren.  Generic drugs: international trends and policy developments in Australia. , 2004, Australian health review : a publication of the Australian Hospital Association.

[46]  J. Emery,et al.  A systematic review of the literature comparing the practices of dispensing and non-dispensing doctors. , 2009, Health policy.

[47]  Matthew E Falagas,et al.  Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. , 2007, The Journal of antimicrobial chemotherapy.

[48]  Killugudi Jayaranam.  Patent threat in emerging economies shifts to biotech , 2008, Nature Biotechnology.

[49]  Joan Costa-Font,et al.  Competition in Off-Patent Drug Markets: Issues, Regulation and Evidence , 2008 .

[50]  A. Rao,et al.  The Effect of Price, Brand Name, and Store Name on Buyers’ Perceptions of Product Quality: An Integrative Review , 1989 .

[51]  Chang-fa Lo.  Asian Journal of WTO and International Health Law and Policy , 2006 .

[52]  Mohamed Azmi Hassali,et al.  Generic Medicines as A Way to Improve Access and Affordability: A Proposed Framework for Pakistan , 2009 .

[53]  N. Homedes,et al.  Multisource drug policies in Latin America: survey of 10 countries. , 2005, Bulletin of the World Health Organization.

[54]  M. D. Dal Poz,et al.  Priorities for research into human resources for health in low- and middle-income countries. , 2010, Bulletin of the World Health Organization.

[55]  S. Simoens,et al.  Generic Medicine Pricing Policies in Europe: Current Status and Impact , 2010, Pharmaceuticals.

[56]  Ingrid Königbauer.  Advertising and generic market entry. , 2007, Journal of health economics.

[57]  C. Correa,et al.  Ownership of knowledge--the role of patents in pharmaceutical R&D. , 2004, Bulletin of the World Health Organization.

[58]  S. E. Nsimba.  Assessing the performance, practices and roles of drug sellers/dispensers and mothers'/guardians' behaviour for common childhood conditions in Kibaha district, Tanzania , 2007, Tropical doctor.

[59]  R. Mpembeni,et al.  How do countries regulate the health sector? Evidence from Tanzania and Zimbabwe. , 2000, Health policy and planning.

[60]  S. Kısa.  Factors that Influence Prescribing Decisions among Turkish Physicians , 2006 .

[61]  C. James,et al.  An unhealthy public-private tension: pharmacy ownership, prescribing, and spending in the Philippines. , 2009, Health affairs.

[62]  B. Wettermark,et al.  Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications , 2010, Expert review of pharmacoeconomics & outcomes research.

[63]  Paul N. Newton,et al.  The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers , 2005, PLoS Medicine.

[64]  Cecilia Pacheco,et al.  Grading of recommendations assessment, development and evaluation( GRADE) , 2012 .

[65]  S. Murray,et al.  ‘Doing’ health policy analysis: methodological and conceptual reflections and challenges , 2008, Health policy and planning.

[66]  N. Kessomboon,et al.  Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA. , 2010, The Southeast Asian journal of tropical medicine and public health.

[67]  H. Leufkens,et al.  Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. , 2009, Bulletin of the World Health Organization.

[68]  Mohamed Azmi Hassali,et al.  Pharmacists' Views on Generic Medicines: A Review of the Literature , 2008 .

[69]  N. Shukla,et al.  Generic Drug Industry in India: The Counterfeit Spin , 2009 .